Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDActual EPS
BioCryst Pharmaceuticals, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 3 | -$0.07 | -$0.07 | -$0.07 |
| Q2 2025 | 1 | -$0.03 | -$0.03 | -$0.03 |
| Q3 2025 | 1 | -$0.01 | -$0.01 | -$0.01 |
| Q4 2025 | 1 | $0.02 | $0.02 | $0.02 |
| Q1 2026 | 1 | $0.00 | $0.00 | $0.00 |
| Q2 2026 | 1 | $0.06 | $0.06 | $0.06 |
| Q3 2026 | 1 | $0.07 | $0.07 | $0.07 |
| Q4 2026 | 1 | $0.10 | $0.10 | $0.10 |
BioCryst Pharmaceuticals, Inc. Earnings Date And Information
BioCryst Pharmaceuticals, Inc. last posted its earnings results on Monday, February 24th, 2025. The company reported $-0.13 earnings per share for the quarter, missing analysts' consensus estimates of $-0.07 by $0.06. The company had revenue of 131.53 M for the quarter and had revenue of 450.71 M for the year. BioCryst Pharmaceuticals, Inc. has generated $0 earnings per share over the last year ($-0.43 diluted earnings per share) and currently has a price-to-earnings ratio of -15.88. BioCryst Pharmaceuticals, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, May 5th, 2025 based on prior year's report dates.
BioCryst Pharmaceuticals, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 02/25/2025 | Q4 2024 | N/A | -$0.13 | N/A | $130.15 M | $131.53 M |
| 11/05/2024 | Q3 2024 | N/A | -$0.07 | N/A | $113.99 M | $117.09 M |
| 08/06/2024 | Q2 2024 | N/A | -$0.06 | N/A | $98.30 M | $109.33 M |
| 05/07/2024 | Q1 2024 | N/A | -$0.17 | N/A | $85.62 M | $92.76 M |
| 02/27/2024 | Q4 2023 | N/A | -$0.31 | N/A | $89.97 M | $93.40 M |
| 11/08/2023 | Q3 2023 | N/A | -$0.19 | N/A | $86.06 M | $86.74 M |
| 08/07/2023 | Q2 2023 | N/A | -$0.40 | N/A | $81.42 M | $82.49 M |
| 05/08/2023 | Q1 2023 | N/A | -$0.28 | N/A | N/A | $68.78 M |
| 02/27/2023 | Q4 2022 | N/A | -$0.38 | N/A | N/A | $79.55 M |
| 11/04/2022 | Q3 2022 | N/A | -$0.23 | N/A | $74.78 M | $75.83 M |
| 08/05/2022 | Q2 2022 | N/A | -$0.32 | N/A | $63.33 M | $65.53 M |
| 05/09/2022 | Q1 2022 | N/A | -$0.40 | N/A | N/A | $49.92 M |
| 02/28/2022 | Q4 2021 | N/A | -$0.10 | N/A | N/A | $47.16 M |
| 11/04/2021 | Q3 2021 | N/A | -$0.33 | N/A | $40.20 M | $40.99 M |
| 08/09/2021 | Q2 2021 | N/A | -$0.24 | N/A | $28.11 M | $49.96 M |
| 05/07/2021 | Q1 2021 | N/A | -$0.36 | N/A | N/A | $19.06 M |
| 03/01/2021 | Q4 2020 | N/A | -$0.34 | N/A | N/A | $4.02 M |
| 11/06/2020 | Q3 2020 | N/A | -$0.26 | N/A | $3.60 M | $6.10 M |
| 08/07/2020 | Q2 2020 | N/A | -$0.24 | N/A | $2.25 M | $2.87 M |
| 05/08/2020 | Q1 2020 | N/A | -$0.24 | N/A | N/A | $4.82 M |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
BioCryst Pharmaceuticals, Inc. Earnings: FAQ's
BioCryst Pharmaceuticals, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, May 5th, 2025 based offlast year's report dates.
The conference call for BioCryst Pharmaceuticals, Inc.'s latest earnings report can be listened to online.
The conference call transcript for BioCryst Pharmaceuticals, Inc.'s latest earnings report can be read online.
BioCryst Pharmaceuticals, Inc. (:BCRX) has a recorded annual revenue of $450.71 M.
BioCryst Pharmaceuticals, Inc. (:BCRX) has a recorded net income of $-88,881,000.BioCryst Pharmaceuticals, Inc. has generated $-0.43 earnings per share over the last four quarters.
BioCryst Pharmaceuticals, Inc. (:BCRX) has a price-to-earnings ratio of -15.88 and price/earnings-to-growth ratio is -0.54.